Literature DB >> 23538156

Long-term efficacy of transcatheter closure of ventricular septal defect in combination with percutaneous coronary intervention in patients with ventricular septal defect complicating acute myocardial infarction: a multicentre study.

Xian-Yang Zhu1, Yong-Wen Qin, Ya-Ling Han, Duan-Zhen Zhang, Ping Wang, Ying-Feng Liu, Ya-Wei Xu, Quan-Min Jing, Kai Xu, Bernard J Gersh, Xiao-Zeng Wang.   

Abstract

AIMS: To assess the immediate and long-term outcomes of transcatheter closure of ventricular septal defect (VSD) in combination with percutaneous coronary intervention (PCI) in patients with VSD complicating acute myocardial infarction (AMI). METHODS AND
RESULTS: Data were prospectively collected from 35 AMI patients who underwent attempted transcatheter VSD closure and PCI therapy in five high-volume heart centres. All the patients who survived the procedures were followed up by chest x-ray, electrocardiogram and echocardiography. Thirteen patients underwent urgent VSD closure in the acute phase (within two weeks from VSD) while the others underwent elective closure at a median of 23 days from VSD occurrence. The percentage of VSD closure device success was 92.3% (36/39) and procedure success was 91.4% (32/35). The incidence of in-hospital mortality was 14.3% (5/35). At a median of 53 months follow-up, only two patients died at 38 and 41 months, respectively, and other patients' cardiac function tested by echocardiography improved significantly compared to that evaluated before discharge.
CONCLUSION: The combination of transcatheter VSD closure and PCI for treating VSD complicating AMI is safe and feasible and is a promising alternative to surgery in patients with anatomically suitable VSD and coronary lesion.

Entities:  

Mesh:

Year:  2013        PMID: 23538156     DOI: 10.4244/EIJV8I11A195

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  7 in total

Review 1.  [Interventional closure of atrial septal defects, patent oval foramen and ventricular septal defects].

Authors:  Marius Hornung; Jennifer Franke; Dani Id; Horst Sievert
Journal:  Herz       Date:  2015-08       Impact factor: 1.443

2.  Systematic review and meta-analysis of the mechanical complications of ischemic heart disease: papillary muscle rupture, left ventricle rupture and post-infarct ventricular septal defect.

Authors:  Paraskevi Morris; Lucy Manuel; Campbell D Flynn; Matteo Matteucci; Daniele Ronco; Giulio Massimi; Federica Torchio; Roberto Lorusso
Journal:  Ann Cardiothorac Surg       Date:  2022-05

Review 3.  Guidance of post myocardial infarction ventricular septal defect and pseudoaneurysm closure.

Authors:  Itzhak Kronzon; Carlos E Ruiz; Gila Perk
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

4.  Decreased tricuspid regurgitation following percutaneous closure of congenital perimembranous ventricular septal defect: immediate and 6-month echocardiographic assessment.

Authors:  Xu-Dong Xu; Su-Xuan Liu; Yuan Bai; Min Zhang; Xian-Xian Zhao; Yong-Wen Qin
Journal:  Heart Vessels       Date:  2014-06-20       Impact factor: 2.037

5.  Abrupt progression of ventricular septal perforation after primary angioplasty for acute myocardial infarction.

Authors:  Takuya Nakahashi; Kenji Sakata; Toyonobu Tsuda; Yoshihiro Tanaka; Miho Ohira; Mika Mori; Mutsuko Takata; Masa-Aki Kawashiri; Hirofumi Takemura; Masakazu Yamagishi; Kenshi Hayashi
Journal:  Cardiovasc Diagn Ther       Date:  2015-12

6.  Flail Tricuspid Leaflet During the Percutaneous Closure of Post-Myocardial Infarction Ventricular Septal Defect.

Authors:  Habibe Kafes; Ozcan Ozeke; Burcu Demirkan; Burak Acar; Firdevs Aysenur Ekizler; Ozlem Karabulut; Hasan Can Konte; Zehra Golbasi; Omac Tufekcioglu; Halil Lutfi Kisacik
Journal:  CASE (Phila)       Date:  2017-08-18

7.  Therapeutic effects of percutaneous coronary intervention on acute myocardial infarction complicated with multiple organ dysfunction syndrome.

Authors:  Dajun Qian; Daqiong Zhou; Huan Liu; Di Xu
Journal:  Pak J Med Sci       Date:  2019 Nov-Dec       Impact factor: 1.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.